Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
about
Human canonical CD157/Bst1 is an alternatively spliced isoform masking a previously unidentified primate-specific exon included in a novel transcript.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
P2860
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@ast
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@en
type
label
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@ast
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@en
prefLabel
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@ast
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@en
P2093
P2860
P356
P1433
P1476
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
@en
P2093
Arnima Bisht
Christian Rohlff
Christina Krupka
Esteban Pombo-Villar
Felix S Lichtenegger
Jan Bögeholz
Jon Terrett
Keith Wilson
Marion Subklewe
P2860
P304
35707-35717
P356
10.18632/ONCOTARGET.16060
P407
P577
2017-03-09T00:00:00Z